Haematopoietic development and leukaemia in Down syndrome

British Journal of Haematology

Volumn 167, Issue 5, 2014, Pages 587-599

  Roberts, Irene ^a   Izraeli, Shai ^b,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Acute megakaryoblastic leukaemia; Down syndrome acute lymphoblastic leukaemia; GATA1; Transient abnormal myelopoiesis; Trisomy 21

Indexed keywords

TRANSCRIPTION FACTOR GATA 1; GATA1 PROTEIN, HUMAN; TUMOR PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CANCER RISK; CELL INTERACTION; CHROMOSOME 21; CLINICAL FEATURE; DISEASE ASSOCIATION; DOWN SYNDROME; ERYTHROID PRECURSOR CELL; GATA1 GENE; GENE EXPRESSION REGULATION; GENE INTERACTION; GENE MUTATION; GENETIC CODE; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HUMAN; LEUKEMIA; LEUKEMOGENESIS; MEGAKARYOCYTE; MOLECULAR PATHOLOGY; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; TRANSIENT ABNORMAL MYELOPOIESIS; TUMOR MICROENVIRONMENT; ADOLESCENT; ANIMAL; B CELL LEUKEMIA; CHILD; GENETICS; HEMATOPOIETIC STEM CELL; METABOLISM; MOUSE; MYELOID LEUKEMIA; MYELOPOIESIS; PATHOLOGY; PRELEUKEMIA; PRESCHOOL CHILD; STEM CELL NICHE;

ADOLESCENT; ANIMALS; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 21; DOWN SYNDROME; GATA1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, B-CELL; LEUKEMIA, MYELOID; MICE; MYELOPOIESIS; NEOPLASM PROTEINS; PRELEUKEMIA; STEM CELL NICHE;

EID: 84939217344     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13096     Document Type: Article

References (110)

1. Ahmed, M., Sternberg, A., Hall, G., Thomas, A., Smith, O., O'Marcaigh, A., Wynn, R., Stevens, R., Addison, M., King, D., Stewart, B., Gibson, B., Roberts, I. & Vyas, P. (2004) Natural history of GATA1 mutations in Down syndrome. Blood, 103, 2480-2489.
2. Ait-Yahya-Graison, E., Aubert, J., Dauphinot, L., Rivals, I., Prieur, M., Golfier, G., Rossier, J., Personnaz, L., Creau, N., Bléhaut, H., Robin, S., Delabar, J.M. & Potier, M.C. (2007) Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes. American Journal of Human Genetics, 81, 475-491.
3. Alford, K.A., Slender, A., Vanes, L., Li, Z., Fisher, E.M., Nizetic, D., Orkin, S.H., Roberts, I. & Tybulewicz, V.L. (2010) Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome. Blood, 115, 2928-2937.
4. Alford, K.A., Reinhardt, K., Garnett, C., Norton, A., Böhmer, K., von Neuhoff, C., Kolenova, A., Marchi, E., Klusmann, J.H., Roberts, I., Hasle, H., Reinhardt, D., Vyas, P. & International Myeloid Leukemia-Down Syndrome Study Group (2011) Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood, 118, 2222-2238.
5. Bercovich, D., Ganmore, I., Scott, L.M., Wainreb, G., Birger, Y., Elimelech, A., Shochat, C., Cazzaniga, G., Biondi, A., Basso, G., Cario, G., Schrappe, M., Stanulla, M., Strehl, S., Haas, O.A., Mann, G., Binder, V., Borkhardt, A., Kempski, H., Trka, J., Bielorei, B., Avigad, S., Stark, B., Smith, O., Dastugue, N., Bourquin, J.P., Tal, N.B., Green, A.R. & Izraeli, S. (2008) Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet, 372, 1484-1492.
6. Birger, Y., Goldber, L., Chlon, T.M., Goldenson, B., Muler, I., Schiby, G., Jacob-Hirsch, J., Rechavi, G., Crispino, J.D. & Izraeli, S. (2013) Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder. Blood, 122, 988-998.
7. Bourquin, J.P., Subramanian, A., Langebrake, C., Reinhardt, D., Bernard, O., Ballerini, P., Baruchel, A., Cave, H., Dastugue, N., Hasle, H., Kaspers, G.L., Lessard, M., Michaux, L., Vyas, P., van Wering, E., Zwaan, C.M., Golub, T.R. & Orkin, S.H. (2006) Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proceedings of the National Academy of Sciences of the United States of America, 103, 3339-3344.
8. Buitenkamp, T.D., Izraeli, S., Zimmermann, M., Forestier, E., Heerema, N.A., van den Heuvel-Eibrink, M.M., Pieters, R., Korbijn, C.M., Silverman, L.B., Schmiegelow, K., Liang, D.C., Horibe, K., Arico, M., Biondi, A., Basso, G., Rabin, K.R., Schrappe, M., Cario, G., Mann, G., Morak, M., Panzer-Grümayer, R., Mondelaers, V., Lammens, T., Cavé, H., Stark, B., Ganmore, I., Moorman, A.V., Vora, A., Hunger, S.P., Pui, C.H., Mullighan, C.G., Manabe, A., Escherich, G., Kowalczyk, J.R., Whitlock, J.A. & Zwaan, C.M. (2014) Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood, 123, 70-77.
9. Carmichael, C.L., Majewski, I.J., Alexander, W.S., Metcalf, D., Hilton, D.J., Hewitt, C.A. & Scott, H.S. (2009) Hematopoietic defects in the Ts1Cje mouse model of Down syndrome. Blood, 113, 1929-1937.
10. Chou, S. & Lodish, H.F. (2010) Fetal liver hepatic progenitors are supportive stromal cells for hematopoietic stem cells. Proceedings of the National Academy of Sciences of the United States of America, 107, 7799-7804.
11. Chou, S.T., Opalinska, J.B., Yao, Y., Fernandes, M.A., Kalota, A., Brooks, J.S., Choi, J.K., Gewirtz, A.M., Danet-Desnoyers, G.A., Nemiroff, R.L. & Weiss, M.J. (2008) Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood, 112, 4503-4506.
12. Chou, S.T., Byrska-Bishop, M., Tober, J.M., Yao, Y., Vandorn, D., Opalinska, J.B., Mills, J.A., Choi, J.K., Speck, N.A., Gadue, P., Hardison, R.C., Nemiroff, R.L., French, D.L. & Weiss, M.J. (2012) Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells. Proceedings of the National Academy of Sciences of the United States of America, 109, 17573-17578.
13. Conti, A., Fabbrini, F., D'Agostino, P., Negri, R., Greco, D., Genesio, R., D'Armeniento, M., Olla, C., Paladini, D., Zannini, M. & Nitsch, L. (2007) Altered expression of mitochondrial and extracellular matrix genes in the heart of human fetuses with chromosome 21 trisomy. BMC Genomics, 8, 268.
14. Dauphinot, L., Lyle, R., Rivals, I., Dang, M.T., Moldrich, R.X., Golfier, G., Ettwiller, L., Toyama, K., Rossier, J., Personnaz, L., Antonarakis, S.E., Epstein, C.J., Sinet, P.M. & Potier, M.C. (2005) The cerebellar transcriptome during postnatal development of the Ts1Cje mouse, a segmental trisomy model for Down syndrome. Human Molecular Genetics, 14, 373-384.
15. David, O., Fiorucci, G.C., Tosi, M.T., Altare, F., Valori, A., Saracco, P., Asinardi, P., Ramenghi, U. & Gabutti, V. (1996) Hematological studies in children with Down syndrome. Pediatric Hematology Oncology, 13, 271-275.
16. Douglas, S.D. (2005) Down syndrome: immunologic and epidemiologic associations-enigmas remain. Journal of Pediatrics, 147, 723-725.
17. Edwards, H., Xie, C., LaFiura, K.M., Dombkowski, A.A., Buck, S.A., Boerner, J.L., Taub, J.W., Matherly, L.H. & Ge, Y. (2009) RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood, 114, 2744-2752.
18. Elagib, K.E., Racke, F.K., Mogass, M., Khetawat, R., Delehanty, L.L. & Goldfarb, A.N. (2003) RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood, 101, 4333-4341.
19. Emmrich, S., Rasche, M., Schöning, J., Reimer, C., Keihani, S., Maroz, A., Xie, Y., Li, Z., Schambach, A., Reinhardt, D. & Klusmann, J.H. (2014) miR-99a/100~125b tricistrons regulate hematopoietic stem and progenitor cell homeostasis by shifting the balance between TGFbeta and Wnt signaling. Genes and Development, 28, 858-874.
20. Forestier, E., Izraeli, S., Beverloo, B., Haas, O., Pession, A., Michalova, K., Stark, B., Harrison, C.J., Teigler-Schlegel, A. & Johansson, B. (2008) Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood, 111, 1575-1583.
21. Gamis, A.S., Alonzo, T.A., Gerbing, R.B., Hilden, J.M., Sorrell, A.D., Sharma, M., Loew, T.W., Arceci, R.J., Barnard, D., Doyle, J., Massey, G., Perentesis, J., Ravindranath, Y., Taub, J. & Smith, F.O. (2011) Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood, 118, 6752-6759.
22. Ganmore, I., Smooha, G. & Izraeli, S. (2009) Constitutional aneuploidy and cancer predisposition. Human Molecular Genetics, 18, R84-R93.
23. Garrett, R.W. & Emerson, S.G. (2006) The role of parathyroid hormone and insulin-like growth factors in hematopoietic niches: physiology and pharmacology. Molecular and Cellular Endocrinology, 288, 6-10.
24. Garrison, M.M., Jeffries, H. & Christakis, D.A. (2005) Risk of death for children with down syndrome and sepsis. Journal of Pediatrics, 147, 748-752.
25. Garzon, R., Pichiorri, R.F., Palumbo, T., Iuliano, R., Cimmino, A., Aqeilan, R., Volinia, S., Bhatt, D., Alder, H., Marcucci, G., Calin, G.A., Liu, C.G., Bloomfield, C.D., Andreeff, M. & Croce, C.M. (2006) MicroRNA fingerprints during human megakaryocytopoiesis. Proceedings of the National Academy of Sciences of the United States of America, 103, 5078-5083.
26. Ge, Y., Jensen, T.L., Stout, M.L., Flatley, R.M., Grohar, P.J., Ravindranath, Y., Matherly, L.H. & Taub, J.W. (2004) The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Research, 64, 728-735.
27. Ge, Y., Stout, M.L., Tatman, D.A., Jensen, T.L., Buck, S., Thomas, R.L., Ravindranath, Y., Matherly, L.H. & Taub, J.W. (2005) GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. Journal of the National Cancer Institute, 97, 226-231.
28. Gefen, N., Binder, V., Zaliova, M., Linka, Y., Morrow, M., Novosel, A., Edry, L., Hertzberg, L., Shomron, N., Williams, O., Trka, J., Borkhardt, A. & Izraeli, S. (2010) Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53. Leukemia, 24, 89-96.
29. Gillespie, K.M., Dix, R.J., Williams, A.J., Newton, R., Robinson, Z.F., Bingley, P.J., Gale, E.A. & Shield, J.P. (2006) Islet autoimmunity in children with Down's syndrome. Diabetes, 55, 3185-3188.
30. Greaves, M. (2003) Pre-natal origins of childhood leukemia. Reviews of Clinical and Experimental Hematology, 7, 233-245.
31. Gribble, S.M., Wiseman, F.K., Clayton, S., Prigmore, E., Langley, E., Yang, F., Maguire, S., Fu, B., Rajan, D., Sheppard, O., Scott, C., Hauser, H., Stephens, P.J., Stebbings, L.A., Ng, B.L., Fitzgerald, T., Quail, M.A., Banerjee, R., Rothkamm, K., Tybulewicz, V.L., Fisher, E.M. & Carter, N.P. (2013) Massively parallel sequencing reveals the complex structure of an irradiated human chromosome on a mouse background in the Tc1 model of Down syndrome. PLoS One, 8, e60482.
32. Groet, J., McElwaine, S., Spinelli, M., Rinaldi, A., Burtscher, I., Mulligan, C., Mensah, A., Cavani, S., Dagna-Bricarelli, F., Basso, G. & Nizetic, D. (2003) Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet, 361, 1617-1620.
33. Hasle, H., Clemmensen, I.H. & Mikkelsen, M. (2000) Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet, 355, 165-169.
34. Hasle, H., Niemeyer, C.M., Chessells, J.M., Baumann, I., Bennett, J.M., Kerndrup, G. & Head, D.R. (2003) A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia, 17, 277-282.
35. Hasle, H., Abrahamsson, J., Arola, M., Karow, A., O'Marcaigh, A., Reinhardt, D., Webb, D.K., van Wering, E., Zeller, B., Zwaan, C.M. & Vyas, P. (2008) Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. Leukemia, 22, 1428-1430.
36. Heald, B., Hilden, J.M., Zbuk, K., Norton, A., Vyas, P., Theil, K.S. & Eng, C. (2007) Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome. Nature Clinical Practice Oncology, 4, 433-438.
37. Henry, E., Walker, D., Wiedmeier, S.E. & Christensen, R.D. (2007) Hematological abnormalities during the first week of life among neonates with Down syndrome: data from a multihospital healthcare system. American Journal of Medical Genetics. Part A, 143, 42-50.
38. Hertzberg, L., Betts, D.R., Raimondi, S.C., Schäfer, B.W., Notterman, D.A., Domany, E. & Izraeli, S. (2007) Prediction of chromosomal aneuploidy from gene expression data. Genes Chromosomes Cancer, 46, 75-86.
39. Hertzberg, L., Vendramini, E., Ganmore, I., Cazzaniga, G., Schmitz, M., Chalker, J., Shiloh, R., Iacobucci, I., Shochat, C., Zeligson, S., Cario, G., Stanulla, M., Strehl, S., Russell, L.J., Harrison, C.J., Bornhauser, B., Yoda, A., Rechavi, G., Bercovich, D., Borkhardt, A., Kempski, H., te Kronnie, G., Bourquin, J.P., Domany, E. & Izraeli, S. (2010) Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood, 115, 1006-1017.
40. de Hingh, Y.C., van der Vossen, P.W., Gemen, E.F., Mulder, A.B., Hop, W.C., Brus, F. & de Vries, E. (2005) Intrinsic abnormalities of lymphocyte counts in children with down syndrome. Journal of Pediatrics, 147, 744-747.
41. Hitzler, J.K., Cheung, J., Li, Y., Scherer, S.W. & Zipursky, A. (2003) GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood, 101, 4301-4304.
42. Hollanda, L.M., Lima, C.S., Cunha, A.F., Albuquerque, D.M., Vassallo, J., Ozelo, M.C., Joazeiro, P.P., Saad, S.T. & Costa, F.F. (2006) An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nature Genetics, 38, 807-812.
43. Izraeli, S. (2005) Chromosome copy number and leukemia-lessons from Down's syndrome. Hematology, 10(Suppl. 1), 164-166.
44. Izraeli, S. (2008) Trisomy 21 tilts the balance. Blood, 112, 4361-4362.
45. Izraeli, S., Vora, A., Zwaan, C.M. & Whitlock, J. (2014) How I treat ALL in Down's syndrome: pathobiology and management. Blood, 123, 35-40.
46. Jiang, J., Jing, Y., Cost, G.J., Chiang, J.C., Kolpa, H.J., Cotton, A.M., Carone, D.M., Carone, B.R., Shivak, D.A., Guschin, D.Y., Pearl, J.R., Rebar, E.J., Byron, M., Gregory, P.D., Brown, C.J., Urnov, F.D., Hall, L.L. & Lawrence, J.B. (2014) Translating dosage compensation to trisomy 21. Nature, 500, 296-300.
47. Karlsson, B., Gustafsson, J., Hedov, G., Ivarsson, S.A. & Anneren, G. (1998) Thyroid dysfunction in Down's syndrome: relation to age and thyroid autoimmunity. Archives of Disease in Childhood, 79, 242-245.
48. Kirsammer, G., Jilani, S., Liu, H., Davis, E., Gurbuxani, S., Le Beau, M.M. & Crispino, J.D. (2008) Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood, 111, 767-775.
49. Kivivuori, S.M., Rajantie, J. & Siimes, M.A. (1996) Peripheral blood cell counts in infants with Down's syndrome. Clinical Genetics, 49, 15-19.
50. Klar, J., Khalfallah, A., Arzoo, P.S., Gazda, H.T. & Dahl, N. (2014) Recurrent GATA1 mutations in Diamond-Blackfan anaemia. British Journal of Haematology, doi: 10.1111/bjh.12919.
51. Klusmann, J.H., Creutzig, U., Zimmermann, M., Dworzak, M., Jorch, N., Langebrake, C., Pekrun, A., Macakova-Reinhardt, K. & Reinhardt, D. (2008) Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood, 111, 2991-2998.
52. Klusmann, J.H., Godinho, F.J., Heitmann, K., Maroz, A., Koch, M.L., Reinhardt, D., Orkin, S.H. & Li, Z. (2010a) Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes and Development, 24, 1659-1672.
53. Klusmann, J.H., Li, Z., Bohmer, K., Maroz, A., Koch, M.L., Emmrich, S., Godinho, F.J., Orkin, S.H. & Reinhardt, D. (2010b) miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes and Development, 24, 478-490.
54. Korbel, J.O., Tirosh-Wagner, T., Urban, A.E., Chen, X.N., Kasowski, M., Dai, L., Grubert, F., Erdman, C., Gao, M.C., Lange, K., Sobel, E.M., Barlow, G.M., Aylsworth, A.S., Carpenter, N.J., Clark, R.D., Cohen, M.Y., Doran, E., Falik-Zaccai, T., Lewin, S.O., Lott, I.T., McGillivray, B.C., Moeschler, J.B., Pettenati, M.J., Pueschel, S.M., Rao, K.W., Shaffer, L.G., Shohat, M., Van Riper, A.J., Warburton, D., Weissman, S., Gerstein, M.B., Snyder, M. & Korenberg, J.R. (2009) The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proceedings of the National Academy of Sciences of the United States of America, 106, 12031-12036.
55. Kusters, M.A., Verstegen, R.H., Gemen, E.F. & de Vries, E. (2009) Intrinsic defect of the immune system in children with Down sydnrome: a review. Clinical and Experimental Immunology, 156, 189-193.
56. Lane, A.A., Chapuy, B., Lin, C.Y., Tivey, T., Li, H., Townsend, E.C., van Bodegom, D., Day, T.A., Wu, S.C., Liu, H., Yoda, A., Alexe, G., Schinzel, A.C., Sullivan, T.J., Malinge, S., Taylor, J.E., Stegmaier, K., Jaffe, J.D., Bustin, M., Te Kronnie, G., Izraeli, S., Harris, M.H., Stevenson, K.E., Neuberg, D., Silverman, L.B., Sallan, S.E., Bradner, J.E., Hahn, W.C., Crispino, J.D., Pellman, D. & Weinstock, D.M. (2014) Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nature Genetics, 46, 618-623.
57. Lange, B.J., Kobrinsky, N., Barnard, D.R., Arthur, D.C., Buckley, J.D., Howells, W.B., Gold, S., Sanders, J., Neudorf, S., Smith, F.O. & Woods, W.G. (1998) Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood, 91, 608-615.
58. Langebrake, C., Creutzig, U. & Reinhardt, D. (2005) Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klinische Pädiatrie, 217, 126-134.
59. Letourneau, A., Santoni, F.A., Bonilla, X., Sailani, M.R., Gonzalez, D., Kind, J., Chevalier, C., Thurman, R., Sandstrom, R.S., Hibaoui, Y., Garieri, M., Popadin, K., Falconnet, E., Gagnebin, M., Gehrig, C., Vannier, A., Guipponi, M., Farinelli, L., Robyr, D., Migliavacca, E., Borel, C., Deutsch, S., Feki, A., Stamatoyannopoulos, J.A., Herault, Y., van Steensel, B., Guigo, R. & Antonarakis, S.E. (2014) Domains of genome-wide gene expression dysregulation in Down's syndrome. Nature, 508, 345-350.
60. Li, Z., Godinho, F.J., Klusmann, J.H., Garriga-Canut, M., Yu, C. & Orkin, S.H. (2005) Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nature Genetics, 37, 613-619.
61. Lin, S.J., Wang, J.Y., Klickstein, L.B., Chuang, K.P., Chen, J.Y., Lee, J.F. & Shieh, C.C. (2001) Lack of age-associated LFA-1 up-regulation and impaired ICAM-1 binding in lymphocytes from patients with Down syndrome. Clinical and Experimental Immunology, 126, 54-63.
62. Lockstone, H.E., Harris, L.W., Swatton, J.E., Wayland, M.T., Holland, A.J. & Bahn, S. (2007) Gene expression profiling in the adult Down syndrome brain. Genomics, 90, 647-660.
63. Loh, R.K., Harth, S.C., Thong, Y.H. & Ferrante, A. (1990) Immunoglobulin G subclass deficiency and predisposition to infection in Down's syndrome. The Pediatric Infectious Diseases Journal, 9, 547-551.
64. MacLean, G.A., Menne, T.F., Guo, G., Sanchez, D.J., Park, I.H., Daley, G.Q. & Orkin, S.H. (2012) Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic induced pluripotent cells. Proceedings of the National Academy of Sciences of the United States of America, 109, 17567-17572.
65. Malinge, S., Izraeli, S. & Crispino, J.D. (2009) Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood, 113, 2619-2628.
66. Malinge, S., Bliss-Moreau, M., Kirsammer, G., Diebold, L., Chlon, T., Gurbuxani, S. & Crispino, J.D. (2012) Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. The Journal of Clinical Investigation, 122, 948-962.
67. Malinge, S., Chlon, T., Doré, L.C., Ketterling, R.P., Tallman, M.S., Paietta, E., Gamis, A.S., Taub, J.W., Chou, S.T., Weiss, M.J., Crispino, J.D. & Figueroa, M.E. (2013) Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes. Blood, 122, e33-e43.
68. Maroz, A., Stachorski, L., Emmrich, S., Reinhardt, K., Xu, J., Shao, Z., Käbler, S., Dertmann, T., Hitzler, J., Roberts, I., Vyas, P., Juban, G., Hennig, C., Hansen, G., Li, Z., Orkin, S., Reinhardt, D. & Klusmann, J.H. (2014) GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia. Leukemia, 28, 1259-1270.
69. Massey, G.V., Zipursky, A., Chang, M.N., Doyle, J.J., Nasim, S., Taub, J.W., Ravindranath, Y., Dahl, G. & Weinstein, H.J. (2006) A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood, 107, 4606-4613.
70. McLean, S., McHale, C. & Enright, H. (2009) Hematological abnormalities in adult patients with Down's syndrome. Irish Journal of Medical Science, 178, 35-38.
71. Mullighan, C.G., Collins-Underwood, J.R., Phillips, L.A., Loudin, M.G., Liu, W., Zhang, J., Ma, J., Coustan-Smith, E., Harvey, R.C., Willman, C.L., Mikhail, F.M., Meyer, J., Carroll, A.J., Williams, R.T., Cheng, J., Heerema, N.A., Basso, G., Pession, A., Pui, C.H., Raimondi, S.C., Hunger, S.P., Downing, J.R., Carroll, W.L. & Rabin, K.R. (2009) Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nature Genetics, 41, 1243-1246.
72. Murphy, M. & Epstein, L.B. (1990) Down syndrome (trisomy 21) thymuses have a decreased proportion of cells expressing high levels of TCR alpha, beta and CD3. A possible mechanism for diminished T cell function in Down syndrome. Clinical Immunology and Immunopathology, 55, 453-467.
73. Ng, A.P., Hyland, C.D., Metcalf, D., Carmichael, C.L., Loughran, S.J., Di Rago, L., Kile, B.T. & Alexander, W.S. (2010) Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome. Blood, 115, 3966-3969.
74. Nichols, K.E., Crispino, J.D., Poncz, M., White, J.G., Orkin, S.H., Maris, J.M. & Weiss, M. (2000) Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nature Genetics, 24, 266-270.
75. Nikolaev, S.I., Santoni, F., Vannier, A., Falconnet, E., Giarin, E., Basso, G., Hoischen, A., Veltman, J.A., Groet, J., Nizetic, D. & Antonarakis, S.E. (2013) Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome. Blood, 122, 554-561.
76. Nik-Zainal, S., Alexandrov, L.B., Wedge, D.C., Van Loo, P., Greenman, C.D., Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L.A., Menzies, A., Martin, S., Leung, K., Chen, L., Leroy, C., Ramakrishna, M., Rance, R., Lau, K.W., Mudie, L.J., Varela, I., McBride, D.J., Bignell, G.R., Cooke, S.L., Shlien, A., Gamble, J., Whitmore, I., Maddison, M., Tarpey, P.S., Davies, H.R., Papaemmanuil, E., Stephens, P.J., McLaren, S., Butler, A.P., Teague, J.W., Jönsson, G., Garber, J.E., Silver, D., Miron, P., Fatima, A., Boyault, S., Langerød, A., Tutt, A., Martens, J.W., Aparicio, S.A., Borg, Å., Salomon, A.V., Thomas, G., Børresen-Dale, A.L., Richardson, A.L., Neuberger, M.S., Futreal, P.A., Campbell, P.J., Stratton, M.R. & Breast Cancer Working Group of the International Cancer Genome Consortium (2012) Mutational processes moulding the genomes of 21 breast cancers. Cell, 149, 179-193.
77. Nizetic, D. & Groet, J. (2012) Tumorigenesis in Down syndrome: big lessons from a small chromosome. Nature Reviews Cancer, 12, 721-732.
78. O'Brien, M.M., Cao, X., Pounds, S., Dahl, G.V., Raimondi, S.C., Lacayo, N.J., Taub, J., Chang, M., Weinstein, H.J., Ravindranath, Y., Inaba, H., Campana, D., Pui, C.H. & Rubnitz, J.E. (2013) Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children's Oncology Group Study POG 9421. Leukemia, 27, 731-734.
79. Pine, S.R., Guo, Q., Yin, C., Jayabose, S., Druschel, C.M. & Sandoval, C. (2007) Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood, 110, 2128-2131.
80. Prandini, P., Deutsch, S., Lyle, R., Gagnebin, M., Delucinge Vivier, C., Delorenzi, M., Gehrig, C., Descombes, P., Sherman, S., Dagna Bricarelli, F., Baldo, C., Novelli, A., Dallapiccola, B. & Antonarakis, S.E. (2007) Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance. American Journal of Human Genetics, 81, 252-263.
81. Prasher, V.P. (1994) Screening of medical problems in adults with Down syndrome. Down Syndrome Research and Practice, 2, 59-66.
82. Rainis, L., Bercovich, D., Strehl, S., Teigler-Schlegel, A., Stark, B., Trka, J., Amariglio, N., Biondi, A., Muler, I., Rechavi, G., Kempski, H., Haas, O.A. & Izraeli, S. (2003) Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood, 102, 981-986.
83. Rainis, L., Toki, T., Pimanda, J.E., Rosenthal, E., Machol, K., Strehl, S., Gotgens, B., Ito, E. & Izraeli, S. (2005) The proto-oncogene ERG in megakaryoblastic leukemias. Cancer Research, 65, 7596-7602.
84. Roberts, I., Alford, K., Hall, G., Juban, G., Richmond, H., Norton, A., Vallance, G., Perkins, K., Marchi, E., McGowan, S., Roy, A., Cowan, G., Anthony, M., Gupta, A., Ho, J., Uthaya, S., Curley, A., Rasiah, S.V., Watts, T., Nicholl, R., Bedford-Russell, A., Blumberg, R., Thomas, A., Gibson, B., Halsey, C., Lee, P.W., Godambe, S., Sweeney, C., Bhatnagar, N., Goriely, A., Campbell, P., Vyas, P. & Oxford-Imperial Down Syndrome Cohort Study Group (2013) GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. Blood, 122, 3908-3917.
85. Roizen, N.J. & Amarose, A.P. (1993) Hematologic abnormalities in children with Down syndrome. American Journal of Medical Genetics, 46, 510-512.
86. Roy, A., Roberts, I., Norton, A. & Vyas, P. (2009) Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis. British Journal of Haematology, 147, 3-12.
87. Roy, A., Cowan, G., Mead, A.J., Filippi, S., Bohn, G., Chaidos, A., Tunstall, O., Chan, J.K., Choolani, M., Bennett, P., Kumar, S., Atkinson, D., Wyatt-Ashmead, J., Hu, M., Stumpf, M.P., Goudevenou, K., O'Connor, D., Chou, S.T., Weiss, M.J., Karadimitris, A., Jacobsen, S.E., Vyas, P. & Roberts, I. (2012) Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21. Proceedings of the National Academy of Sciences of the United States of America, 109, 17579-17584.
88. Russell, L.J., Capasso, M., Vater, I., Akasaka, T., Bernard, O.A., Calasanz, M.J., Chandrasekaran, T., Chapiro, E., Gesk, S., Griffiths, M., Guttery, D.S., Haferlach, C., Harder, L., Heidenreich, O., Irving, J., Kearney, L., Nguyen-Khac, F., Machado, L., Minto, L., Majid, A., Moorman, A.V., Morrison, H., Rand, V., Strefford, J.C., Schwab, C., Tönnies, H., Dyer, M.J., Siebert, R. & Harrison, C.J. (2009) Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood, 114, 2688-2698.
89. Salek-Ardakani, S., Smooha, G., de Boer, J., Sebire, N.J., Morrow, M., Rainis, L., Lee, S., Williams, O., Izraeli, S. & Brady, H.J. (2009) ERG is a megakaryocytic oncogene. Cancer Research, 69, 4665-4673.
90. Sankaran, V.G., Ghazvinian, R., Do, R., Thiru, P., Vergilio, J.A., Beggs, A.H., Sieff, C.A., Orkin, S.H., Nathan, D.G., Lander, E.S. & Gazda, H.T. (2012) Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. The Journal of Clinical Investigation, 122, 2439-2443.
91. Schnittger, S., Dicker, F., Kern, W., Wendland, N., Sundermann, J., Alpermann, T., Haferlach, C. & Haferlach, T. (2011) RUNX1 mutations are frequent in de novo AML with non-complex karyotype and confer an unfavorable prognosis. Blood, 117, 2348-2357.
92. Shochat, C., Tal, N., Bandapalli, O.R., Palmi, C., Ganmore, I., te Kronnie, G., Cario, G., Cazzaniga, G., Kulozik, A.E., Stanulla, M., Schrappe, M., Biondi, A., Basso, G., Bercovich, D., Muckenthaler, M.U. & Izraeli, S. (2011) Gain-of-function mutations in interleukin-7 receptor-{alpha} (IL7R) in childhood acute lymphoblastic leukemias. Journal of Experimental Medicine, 208, 901-908.
93. Starc, T.J. (1992) Erythrocyte macrocytosis in infants and children with Down syndrome. Journal of Pediatrics, 121, 578-581.
94. Taga, T., Saito, A.M., Kudo, K., Tomizawa, D., Terui, K., Moritake, H., Kinoshita, A., Iwamoto, S., Nakayama, H., Takahashi, H., Tawa, A., Shimada, A., Taki, T., Kigasawa, H., Koh, K. & Adachi, S. (2012) Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome. Blood, 120, 1810-1815.
95. Tal, N., Shochat, C., Geron, I., Bercovich, D. & Izraeli, S. (2014) Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia. Cellular and Molecular Life Science, 71, 365-378.
96. Taub, J.W., Mundschau, G., Ge, Y., Poulik, J.M., Qureshi, F., Jensen, T., James, S.J., Matherly, L.H., Wechsler, J. & Crispino, J.D. (2004) Prenetal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood, 104, 1588-1589.
97. Toki, T., Kanezaki, R., Kobayashi, E., Kaneko, H., Suzuki, M., Wang, R., Terui, K., Kanegane, H., Maeda, M., Endo, M., Mizuochi, T., Adachi, S., Hayashi, Y., Yamamoto, M., Shimizu, R. & Ito, E. (2013) Naturally occurring oncogenic GATA1 mutants with internal deletions in transient abnormal myelopoiesis in Down syndrome. Blood, 121, 3181-3184.
98. Tunstall-Pedoe, O., Roy, A., Karadimitris, A., de la Fuente, J., Fisk, N.M., Bennett, P., Norton, A., Vyas, P. & Roberts, I. (2008) Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. Blood, 112, 4507-4511.
99. Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellström-Lindberg, E., Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937-951.
100. Verstegen, R.H., Kusters, M.A., Gemen, E.F. & De Vries, E. (2010) Down syndrome B-lymphocyte subpopulations: intrinsic defect or decreased T-lymphocyte help. Pediatric Research, 67, 563-569.
101. Wechsler, J., Greene, M., McDevitt, M.A., Anastasi, J., Karp, J.E., Le Beau, M.M. & Crispino, J.D. (2002) Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nature Genetics, 32, 148-152.
102. Whitlock, J.A., Sather, H.N., Gaynon, P., Robison, L.L., Wells, R.J., Trigg, M., Heerema, N.A. & Bhatia, S. (2005) Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood, 106, 4043-4049.
103. Xu, G., Nagano, M., Kanezaki, R., Toki, T., Hayashi, Y., Taketani, T., Taki, T., Mitui, T., Koike, K., Kato, K., Imaizumi, M., Sekine, I., Ikeda, Y., Hanada, R., Sako, M., Kudo, K., Kojima, S., Ohneda, O., Yamamoto, M. & Ito, E. (2003) Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood, 102, 2960-2968.
104. Xu, G., Kanezaki, R., Toki, T., Watanabe, S., Takahashi, Y., Terui, K., Kitabayashi, I. & Ito, E. (2006) Physical association of the patient-specific GATA1 mutants with RUNX1 in acute megakaryoblastic leukemia accompanying Down syndrome. Leukemia, 20, 1002-1008.
105. Yoshida, K., Toki, T., Okuno, Y., Kanezaki, R., Shiraishi, Y., Sato-Otsubo, A., Sanada, M., Park, M.J., Terui, K., Suzuki, H., Kon, A., Nagata, Y., Sato, Y., Wang, R., Shiba, N., Chiba, K., Tanaka, H., Hama, A., Muramatsu, H., Hasegawa, D., Nakamura, K., Kanegane, H., Tsukamoto, K., Adachi, S., Kawakami, K., Kato, K., Nishimura, R., Izraeli, S., Hayashi, Y., Miyano, S., Kojima, S., Ito, E. & Ogawa, S. (2013) The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nature Genetics, 45, 1293-1299.
106. Yu, S., Cui, K., Jothi, R., Zhao, D.M., Jing, X., Zhao, K. & Xue, H.H. (2011) GABP controls a critical transcription regulatory module that is essential for maintenace and differentiation of hematopietic stem/progenitor cells. Blood, 117, 2166-2178.
107. Zhang, J. & Lodish, H.F. (2004) Insulin-like growth factor 2 expressed in a novel fetal liver population is a growth factor for hematopoietic stem cells. Blood, 103, 2513-2521.
108. Zipursky, A. (2000) Susceptibility to leukemia and resistance to solid tumors in Down syndrome. Pediatric Research, 47, 704.
109. Zipursky, A. (2003) Transient leukaemia-a benign form of leukaemia in newborn infants with trisomy 21. British Journal of Haematology, 120, 930-938.
110. Zwaan, M.C., Reinhardt, D., Hitzler, J. & Vyas, P. (2008) Acute leukemias in children with Down syndrome. Pediatric Clinics of North America, 55, 53-70.